ClinicalTrials.gg
RecruitingNCT07695363REFIL-2Updated Nov 12, 2026

Restrictive Fluid Management In Liver Transplantation (REFIL)

An interventional study of Low splanchnic blood volume restrictive fluid management strategy and Phlebotomy in Liver Transplantation (LT) and End-stage Liver Disease (ESLD), sponsored by Centre hospitalier de l'Université de Montréal (CHUM). Recruiting at 4 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Centre hospitalier de l'Université de Montréal (CHUM) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Feb 2026, registered Jun 2026).
  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 12, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,364
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in End Stage Liver Disease with a site in Canada — 1 open to participants now, 2 under way, none of them phase 3. End Stage Liver Disease · Canada.

Started
2026
the only one that year
No phase
2 of 12
1 open now
Registered
12th of 12
by date
Lead sponsor
4 of 12
Centre hospitalier de l'Université de Montréal (CHUM)

Among the 12 studies in End Stage Liver Disease with a site in Canada, this one is the only one that started in 2026, is one of 2 with no phase, and was the 12th registered.

End Stage Liver Disease

155 studies on the registry are indexed under End Stage Liver Disease; 31 are open to participants now.

Browse End Stage Liver Disease studies →

Open to participants now

1 of the 12 studies in End Stage Liver Disease with a site in Canada is open now.

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 21 End Stage Liver Disease studies recruiting now, 14 (67%) set no upper age limit and 6 (29%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in End Stage Liver Disease with a site in Canada, or all of them as a file.
02

Study summary

The goal of the REFIL-2 study is to evaluate the effectiveness of a low splanchnic blood volume restrictive fluid management strategy (a strategy that involves limiting fluid administration and prioritizing the use of medications that raise blood pressure during surgery, combined with phlebotomy) in improving patients' recovery after surgery. The study compares the low splanchnic blood volume restrictive fluid management strategy to an optimized cardiac-output liberal fluid management strategy (which involves administering more fluids to raise blood pressure with less reliance on medications). Two primary otucomes and other outcomes important to patients will be measured.

This study (REFIL-2) had a vanguard phase (internal pilot) that included 138 patients (NCT05647733). The patients included in the vanguard pilot phase were not compared between groups but only analyzed descriptively using aggregated data. Only feasibility metrics were compared (see NCT05647733). These 138 patients were thus rolled into the REFIL-2 trial and included in the final sample size reported herein.

Read the detailed description

People with advanced liver disease have poor blood circulation, and too much blood accumulates in the abdomen (a condition known as high intra-abdominal blood volume). However, liver transplantation (LT) is a complex surgery during which the patient can lose a significant amount of blood and blood pressure can fluctuate widely. Therefore, restricting fluids and using medications to raise blood pressure is a strategy that could reduce blood loss and potentially also certain complications after surgery. Furthermore, phlebotomy appears to reduce intra-abdominal blood volume, blood loss, drops in blood pressure, and the need for red blood cell transfusions, potentially improving recovery after surgery. This study therefore aims to determine the best way to manage fluids during a liver transplantation by comparing these two care strategies. Another goal of the study is to measure the cost-effectiveness of the proposed intervention.

Hypothesis: An intraoperative low splanchnic blood volume restrictive fluid management strategy is superior to an optimized cardiac-output liberal fluid management strategy in reducing postoperative severe complications after liver transplantation

Design: Multicenter blinded parallel arm randomized controlled trial

Study population: Adult patients undergoing a liver transplantation for end-stage liver disease (ESLD)

All participants will be followed during their index hospitalization up to post-transplantation Day 30 (whichever comes first), and for 12 months post-transplantation to assess some clinical outcomes, quality of life (QoL), and survival (being alive beyond the index hospitalization).

Participation in this study lasts 12 months.

The results of this study will help determine whether or not to recommend a low splanchnic blood volume restrictive fluid management strategy for people who undergo a liver transplantation.

This study is conducted in two phases: a pilot phase, which demonstrated feasibility across Canada, followed by the current larger-scale phase (REFIL-2).

03

Conditions studied

  • Liver Transplantation (LT)
  • End-stage Liver Disease (ESLD)

Keywords

  • Liver Transplantation
  • Phlebotomy
  • Hemodynamic Management
  • Fluid Management
  • Transfusions
  • Liver Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult ≥ 18 years old
  2. Undergoing liver transplantation (LT)
  3. End-stage liver disease (ESLD) (with or without hepatocellular carcinoma) as the indication for transplantation.

Exclusion criteria

Exclusion Criteria:

  1. Undergoing LT for an indication other than ESLD (e.g., acute liver failure, primary liver cancer without ESLD, retransplantation, amyloid neuropathy, polycystic liver disease, or any other indication not associated with ESLD)
  2. Undergoing combined solid organ transplantations
  3. Any of the following conditions:

    • severe chronic renal failure ( \< 15 ml/minute/1.73 m2 [CKD-EPI equation] or already on renal replacement therapy (RRT))
    • severe anemia ( level \< 80 g/L)
    • hemodynamic instability (norepinephrine equivalent > 10 ug/min)
  4. Physician refusal to enroll the patient.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,364 participants (estimated)

Study arms

  • Experimental
    Restrictive group - Low splanchnic blood volume restrictive fluid management strategy

    A phlebotomy (a procedure where the patient's blood is drawn, similar to a blood donation, without fluid replacement) at the start of the surgery combined with fluid restriction (use of vasopressor preferentially to treat hemodynamic instability with tolerance to relative hypovolemia defined as a Pulse Pressure Variation (PPV) or Stroke Volume (SVV) up to 18%). Fluids will be administered to compensate for blood loss and/or treat severe hemodynamic instability. Blood collected by phlebotomy will always be transfused back at the beginning of the reperfusion phase, during which fluid management will be based on goal-directed therapy (GDT) using either PPV or SV, as in the control group.

    Procedure: Low splanchnic blood volume restrictive fluid management strategy · Procedure: Phlebotomy

  • Active comparator
    Liberal group - Optimized cardiac output liberal fluid management strategy

    Goal-directed therapy (GDT): Patients will receive 250 ml fluid boluses until SV stops increasing by more than 10% or until PPV is below 12%. Fluids will thus be used preferentially to treat hemodynamic instability. Fluids will also be administered to compensate for blood loss and/or treat severe hemodynamic instability.

    Procedure: Optimized cardiac output liberal fluid management strategy

Interventions

  • ProcedureLow splanchnic blood volume restrictive fluid management strategy

    Hemodynamic goal-directed restrictive fluid management strategy

    Also known as: Restrictive

  • ProcedurePhlebotomy

    Blood drawn in a blood donation bag prior to dissection and transfused back after graft reperfusion

  • ProcedureOptimized cardiac output liberal fluid management strategy

    Permissive hemodynamic goal-directed fluid management strategy that optimizes cardiac output throughout surgery

    Also known as: Liberal

06

What researchers measure

Primary outcomes

  1. Number of participants with at least one severe complication up to hospital discharge

    Incidence of at least one severe complications defined as a complication of grade ≥ 3 according to the Dindo-Clavien scale (grade 1 to 5)

    Time frame: Up to hospital discharge (from surgery to hospital discharge) or 30 days, whichever comes first

  2. Number of participants who were transfused at least one unit of red blood cells (RBC) up to hospital discharge

    Incidence of participants transfused at least 1 unit of RBC during surgery or after surgery, up to hospital discharge

    Time frame: Up to hospital discharge (from surgery to hospital discharge) or 30 days, whichever comes first

Secondary outcomes

  1. Number of participants who were transfused at least one unit of red blood cells (RBC) during surgery

    Incidence of at least one RBC transfusion during surgery

    Time frame: Intraoperative (from entrance in the operating room to exit of the operating room)

  2. Number of participants who were transfused at least one unit of red blood cells (RBC) during the perioperative period of surgery

    Incidence of participants transfused at least 1 unit of RBC during the perioperative period of surgery

    Time frame: During surgery (from entrance in the operating to exit of the operating room) and up to 48 hours after surgery (from exit of the operating room to 48 hours after exit of the operating room)

  3. Intraoperative blood loss

    Blood loss as estimated by clinicians

    Time frame: Intraoperative (from entrance in the operating room to exit of the operating room)

  4. Number of participants who were transfused at least one unit of any labile blood product up to hospital discharge

    Incidence of at least one labile blood product transfused from surgery up to hospital discharge

    Time frame: From surgery to hospital discharge (from entrance in the operating room to hospital discharge) or 30 days, whichever comes first

  5. 7-day quality of recovery

    Quality of recovery measured using the 15-item Quality of Recovery (QoR-15) score. Each item is scored on an 11-point numerical rating scale (0-10) for a total between 0 and 150, 0 being the worst possible recovery and 150 being a perfect recovery.

    Time frame: One time point: 7 days after surgery (transplantation)

  6. Number of participants with a 7-day graft dysfunction

    Incidence of graft dysfunction (as per Olthoff's definition)

    Time frame: One time point: 7 days after surgery (transplantation)

  7. Number of participants with a 7-day acute kidney injury (AKI)

    Acute kidney injury (AKI) of KDIGO grade 2 or 3

    Time frame: Over 7 days after surgery (criteria met at any day from surgery to day 7 after surgery)

  8. Number of participants with at least one postoperative hemorrhagic complication up to hospital discharge

    Incidence of at least one postoperative hemorrhagic complication, defined as any bleeding episode associated with a drop of hemoglobin of 20 g/L within 24 hours of bleeding, requiring 2 blood units within 24 hours of bleeding, a surgical hemostasis or an angioembolization.

    Time frame: Up to hospital discharge (from surgery to hospital discharge) or 30 days, whichever comes first

  9. Number of participants with postoperative acute kidney injury (AKI) up to hospital discharge

    Incidence of any postoperative acute kidney injury (AKI) (any grade as per KDIGO criteria) up to hospital discharge

    Time frame: Up to hospital discharge (from surgery to hospital discharge) or 30 days, whichever comes first

  10. Number of participants requiring renal replacement therapy (RRT) up to hospital discharge

    Incidence of postoperative requirement for renal replacement therapy (RRT) \[hemodialysis or hemofiltration\] up to hospital discharge

    Time frame: Up to hospital discharge (from surgery to hospital discharge) or 30 days, whichever comes first

  11. Number of participants with at least one postoperative graft complication up to hospital discharge

    Incidence of at least one postoperative graft complication (primary non-function, vascular, biliary) or retransplantation up to hospital discharge

    Time frame: Up to hospital discharge (from surgery to hospital discharge) or 30 days, whichever comes first

  12. Number of participants with at least one postoperative infectious complication up to hospital discharge

    Incidence of any postoperative infectious complication (other than pneumonia) up to hospital discharge

    Time frame: Up to hospital discharge (from surgery to hospital discharge) or 30 days, whichever comes first

  13. Number of patients with a postoperative wound dehiscence up to hospital discharge

    Incidence of postoperative wound dehiscence or evisceration up to hospital discharge

    Time frame: Up to hospital discharge (from surgery to hospital discharge) or 30 days, whichever comes first

  14. Number of patients with at least one postoperative pulmonary complication up to hospital discharge

    Incidence of any postoperative pulmonary complications (atelectasis, pneumonia, pulmonary oedema) up to hospital discharge

    Time frame: Up to hospital discharge (from surgery to hospital discharge) or 30 days, whichever comes first

  15. Number of participants with at least one postoperative thromboembolic complication up to hospital discharge

    Incidence of at least one thromboembolic complication (deep vein thrombosis, pulmonary embolism, myocardial infraction, stroke, mesenteric ischemia) up to hospital discharge

    Time frame: Up to hospital discharge (from surgery to hospital discharge) or 30 days, whichever comes first

  16. Number of participants with a postoperative ICU readmission up to hospital discharge

    Incidence of ICU readmissions after initial discharge (from the planned postoperative ICU or step-down unit admission) to hospital discharge

    Time frame: From initial ICU discharge (planned postoperative ICU or step-down unit admission) to hospital discharge or 30 days, whichever comes first

  17. Number of days not in an intensive care unit (ICU) at 30 days after surgery (30-day ICU-free days over 30 days)

    Number of days alive and not hospitalized in an ICU. 0 means 30 consecutive days in the ICU or death within 30 days without any day without being in an ICU from surgery to death. 30 means no days hospitalized in an ICU from surgery to the 30-day time point.

    Time frame: From surgery to 30 days after surgery

  18. Number of days without organ support at 30 days after surgery (30-day organ support free days)

    Number of days alive without renal replacement therapy, mechanical ventilation or vasopressor 30 days after surgery. 0 means 30 consecutive days with any organ support or death within 30 days without any day without organ support from surgery to death. 30 means no days with organ support from surgery to the 30-day time point.

    Time frame: From surgery to 30 days after surgery

  19. Hospital length of stay

    Length of hospital stay (days)

    Time frame: From surgery to hospital discharge (up to 12 months after surgery)

  20. Quality of life score

    Quality of life (QoL) score using the 36-item Short Form health survey questionnaire (SF-36). Score ranges from 0 (worst possible health) to 100 (best possible health).

    Time frame: Two time points: 6 and 12 months after surgery

  21. Rate of hospital readmissions

    Number of postoperative hospital readmissions over 12 months after surgery

    Time frame: From hospital discharge after surgery to 12 months after surgery

  22. Rate of 1-year graft complications

    Time to any graft complication (vascular or biliary) to 1 year after surgery

    Time frame: From surgery to 12 months after surgery

  23. Rate of 1-year graft survival

    Time to graft lost (death of retransplantation) up to 1 year after surgery. Censoring will occur if lost to follow-up or 1 year after surgery.

    Time frame: From surgery to 12 months after surgery

  24. Rate of 1-year recipient survival

    Time to death up to 1 year after surgery. Censoring will occur if lost to follow-up or at 12 months after surgery.

    Time frame: From surgery to 12 months after surgery.

  25. Costs of the intervention

    Complication-related costs (total and subcomponent costs including complications, ressource utilization and hospital readmissions)

    Time frame: Up to 12 months post-transplantation

07

Study locations

4 of 4 sites recruiting
08

References and documents

Publications

  • Carrier FM, Chasse M, Wang HT, Aslanian P, Iorio S, Bilodeau M, Turgeon AF. Restrictive fluid management strategies and outcomes in liver transplantation: a systematic review. Can J Anaesth. 2020 Jan;67(1):109-127. doi: 10.1007/s12630-019-01480-y. Epub 2019 Sep 25. PubMed 31556006 ↗
  • Thacker JK, Mountford WK, Ernst FR, Krukas MR, Mythen MM. Perioperative Fluid Utilization Variability and Association With Outcomes: Considerations for Enhanced Recovery Efforts in Sample US Surgical Populations. Ann Surg. 2016 Mar;263(3):502-10. doi: 10.1097/SLA.0000000000001402. PubMed 26565138 ↗
  • Shin CH, Long DR, McLean D, Grabitz SD, Ladha K, Timm FP, Thevathasan T, Pieretti A, Ferrone C, Hoeft A, Scheeren TWL, Thompson BT, Kurth T, Eikermann M. Effects of Intraoperative Fluid Management on Postoperative Outcomes: A Hospital Registry Study. Ann Surg. 2018 Jun;267(6):1084-1092. doi: 10.1097/SLA.0000000000002220. PubMed 28288059 ↗
  • Parikh A, Washburn KW, Matsuoka L, Pandit U, Kim JE, Almeda J, Mora-Esteves C, Halff G, Genyk Y, Holland B, Wilson DJ, Sher L, Koneru B. A multicenter study of 30 days complications after deceased donor liver transplantation in the model for end-stage liver disease score era. Liver Transpl. 2015 Sep;21(9):1160-8. doi: 10.1002/lt.24181. PubMed 25991395 ↗

Related links

Individual participant data

Plan to share: No — End-of-study knowledge translation (KT) planned

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jun 2031, 63 months after the start.

Of 35 non-industry interventional studies with no phase under End Stage Liver Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 72. This study's planned 63 months is above that.

Counting every sponsor, half of 36 studies reached it within 28 months; a quarter within 21 and three quarters within 72.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Nov 2030 → Jun 2031 and completion Nov 2031 → Jun 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2026
First posted
Jul 10, 2026
StartActual
Feb 15, 2026
Primary completionEst.
Jun 1, 2031was Nov 2030
CompletionEst.
Jun 1, 2032was Nov 2031
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 2030→Jun 1, 2031
Nov 12, 2026
Study completion
Nov 2031→Jun 1, 2032
Nov 12, 2026
Enrollment
866→1364
Nov 12, 2026
Primary outcomes
1 edited, 1 added
What changed in the outcomes
  • EditedNumber of participants with at least one severe complication up to hospital dischargeTime frame: Up to hospital discharge (from surgery to hospital discharge) or 30 days, whichever comes first
  • AddedNumber of participants who were transfused at least one unit of red blood cells (RBC) up to hospital dischargeTime frame: Up to hospital discharge (from surgery to hospital discharge) or 30 days, whichever comes first
Nov 12, 2026
Secondary outcomes
1 removed
What changed in the outcomes
  • RemovedNumber of participants who were transfused at least one unit of red blood cells (RBC) up to hospital dischargeTime frame: From surgery to hospital discharge (from entrance in the operating room to hospital discharge) or 30 days, whichever comes first
Nov 12, 2026
Sponsor
Collaborators added: PHRC, Ministry of Health France
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Nov 2030→Jun 1, 2031
    Study completion Nov 2031→Jun 1, 2032
    Enrollment 866→1364
    Primary outcomes 1 edited, 1 added
    What changed in the outcomes
    • EditedNumber of participants with at least one severe complication up to hospital dischargeTime frame: Up to hospital discharge (from surgery to hospital discharge) or 30 days, whichever comes first
    • AddedNumber of participants who were transfused at least one unit of red blood cells (RBC) up to hospital dischargeTime frame: Up to hospital discharge (from surgery to hospital discharge) or 30 days, whichever comes first
    Secondary outcomes 1 removed
    What changed in the outcomes
    • RemovedNumber of participants who were transfused at least one unit of red blood cells (RBC) up to hospital dischargeTime frame: From surgery to hospital discharge (from entrance in the operating room to hospital discharge) or 30 days, whichever comes first
    Sponsor Collaborators added: PHRC, Ministry of Health France
    + 2 other changes: description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07695363
Collaborators
Canadian Institutes of Health Research (CIHR), Canadian Donation and Transplantation Research Program (CDTRP), Canadian Perioperative Anesthesia Clinical Trial (PACT) Group, PHRC, Ministry of Health France
Responsible party
Sponsor
First posted
Jul 10, 2026
Start date
Feb 15, 2026
Primary completion
Jun 1, 2031 (estimated)
Completion
Jun 1, 2032 (estimated)
Last update
Nov 12, 2026

Study contacts

Manuela Mbacfou, MSc
Contact
manuela.mbacfou.temgoua.chum@ssss.gouv.qc.ca
514-890-8000 ext. 31576
François Martin Carrier, MD
Contact
francois.martin.carrier.med@ssss.gouv.qc.ca
514-890-8000
François Martin Carrier, MD
principal investigator · Centre hospitalier de l'Université de Montréal (CHUM)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion